Rep. Ro Khanna reported roughly $99,000 worth of purchases in Abbott Laboratories shares during a week of trading in February, according to newly filed congressional disclosures.
The California Democrat’s filing shows four separate purchases of ABT, the healthcare giant known for its diabetes monitoring systems and diagnostic platforms. The transactions occurred between Feb. 17 and Feb. 24 and were attributed to both a spouse and a dependent child, according to the disclosure.
Abbott Laboratories, a diversified medical products manufacturer with a market capitalization of about $187.7 billion, trades on the New York Stock Exchange and recently closed around $108.03 per share. The company generates revenue across diagnostics, cardiovascular devices, nutrition products, and branded generic pharmaceuticals. Investors frequently track Abbott for its exposure to long-term growth in medical technology and recurring healthcare demand, particularly through products like its FreeStyle Libre continuous glucose monitoring system.
The February filing shows a cluster of purchases made over two consecutive days before a larger trade later in the month:
- Feb. 17, 2026 — Buy, $1,000–$15,000 (Spouse)
- Feb. 18, 2026 — Buy, $1,000–$15,000 (Spouse)
- Feb. 18, 2026 — Buy, $1,000–$15,000 (Dependent Child)
- Feb. 24, 2026 — Buy, $50,000–$100,000 (Dependent Child)
Because congressional disclosures report transactions in broad dollar ranges, the exact amount invested is not public. Based on the reported ranges, the purchases together amount to an estimated value of roughly $99,000.
The final trade on Feb. 24 stands out as the largest single transaction, potentially representing up to $100,000 invested in Abbott stock. Earlier trades during the week appear to be smaller incremental purchases.
Khanna is among the more active traders in Congress, with approximately 19,625 transactions recorded across his career disclosures. Like all members of Congress, he is required to report stock trades within 45 days under the STOCK Act, a 2012 law intended to increase transparency and prevent lawmakers from profiting on nonpublic information.
Abbott is also a widely held name on Capitol Hill. At least 58 lawmakers have reported trades in the company, reflecting the stock’s status as a major component of healthcare and large-cap investment portfolios.
Khanna serves on several House panels, including the House Committee on Armed Services and the House Committee on Oversight and Government Reform, as well as the House Select Committee on the Strategic Competition Between the United States and the Chinese Communist Party. His committee assignments primarily focus on defense policy, government oversight, and technology-related issues rather than direct healthcare regulation.
The February transactions add to a long record of activity in financial disclosures associated with the California Democrat’s household. Investors and transparency advocates often monitor filings like these for patterns across the latest congressional trades, particularly when lawmakers or their families accumulate positions in large publicly traded companies.
For Abbott, the purchases come as the healthcare conglomerate continues expanding its diagnostics and medical device businesses, areas that analysts expect to drive steady cash flow and long-term demand across global healthcare markets.